RxDoctor Payments Data

Juda Carter

Family · Jacksonville, ALNPI 1164526711

Payments from drug & device makers

$701in general payments, 2019–2025

Across 33 payments — averaging $21.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$454
  • Alnylam Pharmaceuticals Inc.$56
  • Lilly USA, LLC$31
  • GSK$29
  • Intra-sana Laboratories$20
  • Exact Sciences$20
  • plus $91 from 7 others

What the payments were for

  • Food & beverage$701100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$701 in reported general payments places this provider in the 55th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$36,698
Medicare patients
188
Services billed
2,057

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide69$79,337
OzempicSemaglutide62$59,161
FarxigaDapagliflozin Propanediol70$44,221
JardianceEmpagliflozin62$41,785
RybelsusSemaglutide28$36,215
TrulicityDulaglutide28$33,536
JanuviaSitagliptin Phosphate24$27,369
XareltoRivaroxaban15$24,478
EliquisApixaban22$24,267
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$14,883
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$10,594
Repatha SureclickEvolocumab11$10,230
Icosapent Ethyl15$6,555
Lantus SolostarInsulin Glargine,hum.Rec.Anlog67$5,689
Rosuvastatin Calcium251$4,626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$31$112,87397 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$454$59,34699 claims
Boehringer IngelheimJardiance$13$41,78562 claims
GSKTrelegy Ellipta, Breo Ellipta$29$19,04832 claims
AbbVieSynthroid$13$1,07315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,415 family providers in Alabama.

Other family in Jacksonville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →